Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study

Introduction For hemodialysis patients at high risk of bleeding, a regional anticoagulant can be used, such as citrate or nafamostat mesylate (NM). The objective of this study was to evaluate NM as an alternative to citrate for anticoagulation in hemodialysis patients at high risk of bleeding.Method...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jiangtao Li, Lirui Wang, Yuqiu Lu, Ying Zhou, Yue Chen
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis Group 2025-12-01
Serie:Renal Failure
Soggetti:
Hemodialysis
anticoagulation
nafamostat mesylate
citrate
Accesso online:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2464830
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi